.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Priya Rastogi, MD

Articles

MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer

November 25th 2025

Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.